Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

61. Abemaciclib (Verzenio) - Metastatic Breast Cancer

Abemaciclib (Verzenio) - Metastatic Breast Cancer Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you

2019 Health Canada - drugs and medical devices

62. Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III Breast Cancer

of disease recurrence, the association of distant metastasis and biomarker profile in early-stage breast cancer has not been adequately studied in prospective studies of staging investigation. The benefit and risks of the routine use of biomarker profiles to assess for distant metastasis is still unclear and, thus, its use to guide decisions on imaging staging for clinical early-stage breast cancer is not recommended regardless of whether the patient is going for neoadjuvant therapy. Guideline 1-14 (...) , and PET/CT may add unnecessary anxiety and resource use. Therefore, the use of PET/CT, as part of the baseline staging in women clinically diagnosed with early-stage breast cancer (I, II) and with no symptoms for distant metastasis is not recommended at this time. ? Although women with triple negative and human epidermal growth factor receptor 2- positive (HER2+) breast cancer have an increased risk of disease recurrence, the association of distant metastasis and biomarker profile in early-stage

2019 Cancer Care Ontario

63. Ribociclib, Breast Neoplasms, Benefit Assessment, NCT02422615, NCT02278120

breast cancer were included. Randomization was in a 1:1 ratio and was stratified according to the presence of liver or lung metastases (yes/no), prior chemotherapy for advanced disease (yes/no) and endocrine combination partner (tamoxifen + goserelin or NSAI + goserelin). All patients in the study were pre- or perimenopausal. Their tumours had to be not amenable to resection or radiotherapy with curative intent. In addition, the patients had to have an Eastern Cooperative Oncology Group Performance (...) Ribociclib, Breast Neoplasms, Benefit Assessment, NCT02422615, NCT02278120 Extract 1 Translation of Sections 2.1 to 2.8 of the dossier assessment Ribociclib (Mammakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 April 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-06 Ribociclib (breast cancer

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

64. Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women.

preoperative radiography and radionuclide bone scanning performed on stage I asymptomatic breast cancer patients [5]. Only 1 of 633 patients with stage I disease had metastatic bone disease detected. Several other nonrandomized clinical studies have also documented the low yield and lack of utility of radionuclide bone scanning for patients with stage I breast carcinoma [6-9]. Despite the low yield of bone scans, many clinicians order baseline bone scans for comparison with subsequent scans performed when (...) to be <0.5% in asymptomatic women who had routine chest radiographs after the diagnosis of stage I breast carcinoma [5,19,20]. In a study of 412 women with newly diagnosed breast cancer, chest radiographs only showed metastases in women previously classified as having stage III disease [21]. Furthermore, false-positive chest radiographs can lead to expensive diagnostic workups. Two large Italian randomized control studies failed to show a significant outcome benefit when routine chest radiography

2019 American College of Radiology

65. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Full Text available with Trip Pro

Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Published findings on breast cancer risk associated with different types of menopausal hormone therapy (MHT) are inconsistent, with limited information on long-term effects. We bring together the epidemiological evidence, published and unpublished, on these associations, and review the relevant randomised evidence.Principal analyses used (...) never users.During prospective follow-up, 108 647 postmenopausal women developed breast cancer at mean age 65 years (SD 7); 55 575 (51%) had used MHT. Among women with complete information, mean MHT duration was 10 years (SD 6) in current users and 7 years (SD 6) in past users, and mean age was 50 years (SD 5) at menopause and 50 years (SD 6) at starting MHT. Every MHT type, except vaginal oestrogens, was associated with excess breast cancer risks, which increased steadily with duration of use

2019 Lancet

66. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. (Abstract)

Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. Surgery has been used as part of breast cancer treatment for centuries; however any surgical procedure has the potential risk of infection. Infection rates for surgical treatment of breast cancer are documented at between 3% and 15%, higher than average for a clean surgical procedure. Pre- and perioperative antibiotics have been found to be useful in lowering infection rates in other surgical groups, yet (...) there is no consensus on the use of prophylactic antibiotics for breast cancer surgery. This is an update of a Cochrane Review first published in 2005 and last updated in 2014.To determine the effects of prophylactic (pre- or perioperative) antibiotics on the incidence of surgical site infection (SSI) after breast cancer surgery.For this fourth update, in August 2018 we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE (including In-Process

2019 Cochrane

67. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Full Text available with Trip Pro

trials were combined by using a profile likelihood random-effects model.Probability of breast cancer in individuals (area under the receiver operating characteristic curve [AUC]); incidence of breast cancer, fractures, thromboembolic events, coronary heart disease events, stroke, endometrial cancer, and cataracts; and mortality.A total of 46 studies (82 articles [>5 million participants]) were included. Eighteen risk assessment methods in 25 studies reported low accuracy in predicting the probability (...) Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Medications to reduce risk of breast cancer are effective for women at increased risk but also cause adverse effects.To update the 2013 US Preventive Services Task Force systematic review on medications to reduce risk of primary (first diagnosis) invasive breast cancer in women.Cochrane Central Register of Controlled Trials

2019 JAMA

68. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

in women without preexisting breast cancer or ductal carcinoma in situ.The USPSTF found convincing evidence that risk assessment tools can predict the number of cases of breast cancer expected to develop in a population. However, these risk assessment tools perform modestly at best in discriminating between individual women who will or will not develop breast cancer. The USPSTF found convincing evidence that risk-reducing medications (tamoxifen, raloxifene, or aromatase inhibitors) provide at least (...) a moderate benefit in reducing risk for invasive estrogen receptor-positive breast cancer in postmenopausal women at increased risk for breast cancer. The USPSTF found that the benefits of taking tamoxifen, raloxifene, and aromatase inhibitors to reduce risk for breast cancer are no greater than small in women not at increased risk for the disease. The USPSTF found convincing evidence that tamoxifen and raloxifene and adequate evidence that aromatase inhibitors are associated with small to moderate harms

2019 JAMA

69. Taxanes for adjuvant treatment of early breast cancer. (Abstract)

versus non-taxane-containing regimens in women with operable breast cancer were included. Studies of women receiving neoadjuvant chemotherapy were excluded.Two review authors independently extracted data and assessed risk of bias and quality of the evidence using the GRADE approach. Hazard ratios (HRs) were derived for time-to-event outcomes, and meta-analysis was performed using a fixed-effect model. The primary outcome measure was overall survival (OS); disease-free survival (DFS) was a secondary (...) of studies supports the use of taxane-containing adjuvant chemotherapy regimens, with improvement in overall survival and disease-free survival for women with operable early breast cancer. This benefit persisted when analyses strictly compared a taxane-containing regimen versus the same regimen without a taxane or the same regimen with another drug that was substituted for the taxane. Preliminary evidence suggests that taxanes are more effective for women with lymph node-positive disease than for those

2019 Cochrane

70. Internal mammary node irradiation for people with high-risk early breast cancer

Internal mammary node irradiation for people with high-risk early breast cancer Internal mammary node irradiation - Health Technology Wales > Internal mammary node irradiation Internal mammary node irradiation Topic Status Complete Internal mammary node irradiation for people with high-risk early breast cancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence (...) on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER031 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking at this document because We may like to contact

2019 Health Technology Wales

71. Partial breast irradiation for people with early breast cancer

Partial breast irradiation for people with early breast cancer Partial breast irradiation - Health Technology Wales > Partial breast irradiation Partial breast irradiation Topic Status Complete Partial breast irradiation for people with early breast cancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation (...) discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER029 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking at this document because We may like to contact you by email to find out more about how you used

2019 Health Technology Wales

72. Breast Cancer: Medication Use to Reduce Risk

cancer. The USPSTF found that the benefits of taking tamoxifen, raloxifene, and aromatase inhibitors to reduce risk for breast cancer are no greater than small in women not at increased risk for the disease. Potential Harms of Risk-Reducing Medications The USPSTF found convincing evidence that tamoxifen and raloxifene are associated with small to moderate harms. Tamoxifen and raloxifene increase risk for venous thromboembolic events (VTEs); tamoxifen increases risk more than raloxifene (...) to reduce risk of breast cancer outweigh the potential benefits in women not at increased risk for the disease. Clinicians should discuss the limitations of current clinical risk assessment tools for predicting an individual’s future risk of breast cancer when discussing the benefits and harms of risk-reducing medications with women. Clinical Considerations Patient Population Under Consideration This recommendation applies to asymptomatic women 35 years and older, including women with previous benign

2019 U.S. Preventive Services Task Force

73. Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy

Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy Axillary radiotherapy - Health Technology Wales > Axillary radiotherapy Axillary radiotherapy Topic Status Complete Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy. Summary This report (...) was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER030 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services

2019 Health Technology Wales

74. Resection of Cavity Shave Margins in Stage 0-III Breast Cancer Patients Undergoing Breast Conserving Surgery: A Prospective Multicenter Randomized Controlled Trial (Abstract)

Resection of Cavity Shave Margins in Stage 0-III Breast Cancer Patients Undergoing Breast Conserving Surgery: A Prospective Multicenter Randomized Controlled Trial Single-center studies have demonstrated that resection of cavity shave margins (CSM) halves the rate of positive margins and re-excision in breast cancer patients undergoing partial mastectomy (PM). We sought to determine if these findings were externally generalizable across practice settings.In this multicenter randomized (...) controlled trial occurring in 9 centers across the United States, stage 0-III breast cancer patients undergoing PM were randomly assigned to either have resection of CSM ("shave" group) or not ("no shave" group). Randomization occurred intraoperatively, after the surgeon had completed their standard PM. Primary outcome measures were positive margin and re-excision rates.Between July 28, 2016 and April 13, 2018, 400 patients were enrolled in this trial. Four patients (2 in each arm) did not meet inclusion

2019 EvidenceUpdates

75. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable Breast Cancer

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable Breast Cancer Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO (...) .19.00948 Journal of Clinical Oncology - published online before print June 17, 2019 PMID: Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline , MD, PhD 1 x N. Lynn Henry ; , PhD 2 x Mark R. Somerfield ; , MD 3 x Vandana G. Abramson ; , MD 2 x Nofisat Ismaila ; , MD 4 x Kimberly H. Allison ; , MD 5 x Carey K. Anders ; , MS, MFA 6 x Diana T. Chingos ; , MD 7 x Andrea

2019 American Society of Clinical Oncology Guidelines

76. Clinical utility of genomic signatures in early-stage breast cancer

Clinical utility of genomic signatures in early-stage breast cancer Clinical utility of genomic signatures in early-stage breast cancer - INAHTA Brief

2019 Haute Autorite de sante

77. Clinical utility of genomic signatures in early-stage breast cancer

Clinical utility of genomic signatures in early-stage breast cancer INAHTA Brief Issue 2019 Title Clinical utility of genomic signatures in early-stage breast cancer Agency HAS, French National Authority for Health (Haute Autorité de santé) 5 avenue du Stade de France – F 93218 La Plaine Cedex, France Tel: +33 (0)1 55 93 70 00, contact.seap@has-santé.fr, www.has-sante.fr Reference ISBN number 978-2-11-152376-0, link to full report https://www.has-sante.fr/portail/jcms/c_2748998/fr/utilite (...) aids for the prescribing of adjuvant chemotherapy (ACT) in certain cases of early breast cancer. Conclusions and results The HAS report concludes that GS are not intended to replace standard clinicopathological criteria (SCPC), which are considered to play a crucial role in the prescribing of ACT for early breast cancer. In light of inadequate 2 and/or lack of clinical data respectively found in first and second generation tests, the HAS considers it to be premature to recommend routine use of GS

2019 Haute Autorite de sante

78. Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial (Abstract)

Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial Persistent postsurgical pain is defined as pain localized to the area of surgery of a duration of ≥2 months and is, unfortunately, a common complication after breast cancer surgery. Although there is insufficient evidence to support any preventative strategy, prior literature suggests the possible efficacy (...) of intravenous lidocaine and perioperative pregabalin in preventing persistent pain after surgery. To determine feasibility of conducting a larger definitive trial, we conducted a multicenter 2 × 2 factorial, randomized, placebo-controlled pilot trial of 100 female patients undergoing breast cancer surgery. Patients were randomized to receive an intraoperative lidocaine infusion (1.5 mg/kg bolus followed by 2 mg/kg/h) or placebo and perioperative pregabalin (300 mg preoperatively, 75 mg twice daily for 9

2019 EvidenceUpdates

79. Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging (Abstract)

Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging Federal legislation proposes requiring that screening mammography reports to practitioners and women incorporate breast density information and that women with dense breasts discuss supplemental imaging with their practitioner given their increased risk of interval breast cancer. Instead of discussing supplemental imaging with all women with dense breasts, it may (...) be more efficient to identify women at high risk of advanced breast cancer who may benefit most from supplemental imaging.To identify women at high risk of advanced breast cancer to target woman-practitioner discussions about the need for supplemental imaging.This prospective cohort study assessed 638 856 women aged 40 to 74 years who had 1 693 163 screening digital mammograms taken at Breast Cancer Surveillance Consortium (BCSC) imaging facilities from January 3, 2005, to December 31, 2014. Data

2019 EvidenceUpdates

80. Abemaciclib (Verzenios) for the treatment of metastatic breast cancer

Abemaciclib (Verzenios) for the treatment of metastatic breast cancer Abemaciclib (Verzenios®) for the treatment of metastatic breast cancer | Report | National Health Care Institute You are here: Abemaciclib (Verzenios®) for the treatment of metastatic breast cancer Search within English part of National Health Care Institute Search Abemaciclib (Verzenios®) for the treatment of metastatic breast cancer Zorginstituut Nederland has completed its assessment of abemaciclib (Verzenios® (...) ) for the treatment of metastatic breast cancer. Due to its expected high costs the Minister of Health, Welfare and Sport (VWS) has placed tisagenlecleucel in the so-called ‘waiting room’ or ‘sluice’ for expensive drugs. These products can only be accepted into the insured package after the Zorginstituut has advised on their inclusion in the insured package and, where applicable, subject to Ministry negotiations to arrive at a financial arrangement with the supplier. The Zorginstituut was advised by two

2019 National Health Care Institute (Zorginstituut Nederland)